Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Seite 2

“There remains a high unmet need for effective treatments in relapsed/refractory (R/R) CD30+ lymphomas. We are encouraged by the data generated from the first patients treated with cbNK cells pre-complexed with AFM13,” said Dr. Rezvani. “The results suggest this combination is facilitating clinical responses with minimal toxicity, warranting further study as we continue to explore novel cell therapies for our patients.”  

As of March 31, 2021, three patients have been dosed with two cycles of therapy in dose cohort 1 (1x10⁶ AFM13-cbNK/kg) and one patient has received a single cycle of therapy in dose cohort 2 (1x10⁷ AFM13-cbNK/kg). The study is currently enrolling patients in the second dose cohort of NK cells, and further updates are expected later in 2021. Results from the first cycle of the first dose cohort are being presented by Dr. Rezvani at AACR, and Affimed is supplementing the data with best responses as of March 31, 2021, as summarized below.

Patient number	cbNK Cell Dose	Patient	Cancer Type	Prior Treatment	CRS/ Neurotoxicity/ GVHD	Best Response
Cohort 1 – completed
#1	1x106 / kg	43-year-old-male	Hodgkin lymphoma	4 lines of therapy (ABVD, ICE, brentuximab vedotin, nivolumab + ruxolitinib)	None	Partial response
#2	1x106 / kg	31-year-old-male	Hodgkin lymphoma	14 lines of therapy (ABVD, brentuximab vedotin, HDACi/P13Ki, pembrolizumab, nivolumab, allo-HSCT, hypercytoxan, ibrutinib, niraparib, bendamustine, everolimus)	None	Partial response
#3	1x106 / kg	53-year-old-female	Hodgkin lymphoma	5 lines of therapy (ABVD, ICE, brentuximab vedotin, nivolumab, GemOx)	None	Complete response after cycle 2
Cohort 2 – ongoing (1 of 3 patients enrolled)
#4	1x107 / kg	26-year-old-male	Hodgkin lymphoma	9 lines of therapy (ABVD, ICE + brentuximab vedotin, radiation, nivolumab, CD30-CART, TTI-622, brentuximab vedotin + bendamustine, allo-HSCT, brentuximab vedotin + bendamustine with brentuximab vedotin maintenance)	None	Complete response

ABVD = Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine (DTIC)